Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most statements regarding FDA-approved IBS-D indication and general safety cautions are supported, including contraindications related to gallbladder absence, alcoholism, and pancreatitis. However, several mechanistic and risk statements are not fully supported by the provided label excerpts (e.g., opioid receptor mechanism claims and specific “not recommended for severe liver problems” phrasing), and one claim about constipation/diagnostic reassessment is not supported by the provided label text.
Category Scores
Accurate Statements
Eluxadoline (brand name Viberzi) is a prescription medicine for adults with irritable bowel syndrome with diarrhea (IBS-D).
Indications and Usage: “VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).” (Section 1)
Eluxadoline is specifically indicated for IBS with diarrhea (IBS-D).
Indications and Usage: “...indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).” (Section 1)
Eluxadoline is not recommended for patients with no gallbladder (or a history of gallbladder removal).
Contraindications: “Without a gallbladder...” (Section 4); “VIBERZI is contraindicated in patients without a gallbladder.” (Section 5.1)
Eluxadoline is not recommended for patients with a history of pancreatitis, or other pancreatitis risk factors.
Contraindications: “With a history of pancreatitis; or structural diseases of the pancreas...” (Section 4); Pancreatitis warning context (Section 5.1)
Eluxadoline is not recommended for patients with alcohol misuse or certain heavy alcohol use patterns.
Contraindications: “With alcoholism, alcohol abuse or alcohol addiction, or in patients who drink more than 3 alcoholic beverages per day...” (Section 4)
Unsupported Statements
Eluxadoline works in the gut to reduce diarrhea and abdominal pain by acting on opioid receptors in the gastrointestinal tract.
Mechanism excerpt provided (Section 12.1) states opioid receptor interactions in the gut/animals, but the label excerpt does not specifically tie this to “reduce diarrhea and abdominal pain” as a stated mechanism of action. The claim also specifies “acting on opioid receptors in the gastrointestinal tract,” which is only partially supported by the provided mechanism text.
Eluxadoline reduces bowel frequency in IBS-D by targeting opioid receptors in the gastrointestinal tract.
The provided excerpts do not state “reduces bowel frequency” or link bowel frequency reduction to opioid receptor targeting. Section 14 provides efficacy in IBS-D but not this specific phrasing.
Eluxadoline improves related discomfort in IBS-D.
The provided excerpts do not mention improvement in “related discomfort.” While efficacy is established for IBS-D (Section 14), “discomfort” is not supported in the supplied text.
Eluxadoline is not indicated for constipation-type IBS (IBS-C).
The provided label excerpts confirm an indication for IBS-D but do not explicitly state that it is “not indicated” for IBS-C.
Eluxadoline is not recommended for patients with severe liver problems.
The label provided specifies contraindication for severe hepatic impairment (Child-Pugh Class C) rather than using the phrase “not recommended for patients with severe liver problems.” The claim is only partially supported and is framed more broadly than the label excerpt.
If IBS symptoms shift toward constipation or if diarrhea does not improve, clinicians may reassess diagnosis and consider alternatives rather than continuing an IBS-D–targeted therapy.
The provided label includes a warning to discontinue VIBERZI in patients who develop severe constipation (Section 2; Warning 5.4), but the excerpt does not support the broader recommendation about reassessing diagnosis/considering alternatives for constipation shift or for diarrhea non-improvement.
Contradictions
Important Omissions
The AI response did not mention the specific labeled dosing instructions (100 mg twice daily with food, or 75 mg twice daily with food for certain patients), which are central to dosage and administration accuracy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-related statements (gallbladder absence, pancreatitis history, alcoholism) align with contraindications. However, other statements are either broader than the label or not supported (e.g., general “severe liver problems” framing; mechanistic and symptom-outcome claims; and advice about reassessment/alternatives not supported by the provided warning/discontinuation text).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several mechanistic/outcome and clinical-decision statements are not supported by the provided label excerpts, and one hepatic statement is imprecisely framed compared with the label’s Child-Pugh Class C contraindication.
Suggested Improvement
Limit claims to label-supported language: use the label’s contraindication framing for hepatic impairment (Child-Pugh Class C) and explicitly supported warnings (e.g., discontinue for severe constipation). Avoid unlabelled wording such as “related discomfort,” “bowel frequency reduction” tied to receptor targeting, and “reassess diagnosis/consider alternatives” when diarrhea does not improve, unless directly supported in the provided label text.